However, CB2 inverse agonist SMM-189 (6 mg/kg i.p. twice daily, after stopping 1 h of status epilepticus) was anti-inflammatory and neuroprotective, improving functional recovery, reducing levels of pro-inflammatory cytokines, and reducing activated microglia marker Iba1 and astrocyte marker GFAP mRNA in the hippocampus. Here, CNR2 is linked to status epilepticus.